Condition: Fibromuscular Dysplasia · Spontaneous Coronary Artery Dissection · Cervical Artery Dissection · Sponsor: Icahn School of Medicine at Mount Sinai
The purpose of this study has evolved and expanded since its inception. Originally the intent was to establish the functional, molecular and genetic profile of fibroblasts from Fibromuscular Dysplasia (FMD) patients as compared to carefully matched control subjects. While this remains among the objectives, the study has been expanded to undertake a fully powered cross-tissue systems genetics analysis of FMD, and now also the related arteriopathies spontaneous coronary artery dissection (SCAD) and cervical artery dissection (CvAD). The overall objective is to disclose the core biologic mechanisms of these disorders.
This description comes directly from the study's public registry record.
Jason Kovacic, MD, PhD · 212-241-7014 · jason.kovacic@mountsinai.org
Jeffrey Olin, DO · jeffrey.olin@mountsinai.org
Always discuss trial participation with your own doctor first.
| Icahn School of Medicine at Mount Sinai | New York, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT01967511